Psychedelic Medicine


The Spring 2023 edition of the Psychedelic Medicine Association Journal Club

Log In To Watch the Recording

*Exclusive for members.

Thursday, March 30th at 5 pm Pacific, 8 pm Eastern >> Log In To Watch the Recording >>

Join us for the spring 2023 edition of:

The Psychedelic Medicine Association Journal Club


Brandon Weiss, PhD

Postdoctoral Researcher, Centre for Psychedelic Research and Neuropsychopharmacology at Imperial College London

Brandon is a Clinical Psychologist exploring the psychological and physiological ways in which psychedelics impact personality, well-being, and post-traumatic stress. Brandon currently serves as a postdoctoral researcher in the Centre for Psychedelic Research and Neuropsychopharmacology, where he leads the laboratory-based self-blinding microdosing study. This study utilizes a novel self-blinding framework through which participants blind themselves to whether they are ingesting placebo or a psychedelic microdoses. Brandon is also active in investigating the therapeutic effects of indigenous psychedelic practices such as ayahuasca and ibogaine for the special forces veteran population. He completed his PhD at the University of Georgia and clinical training at the San Diego VA / UCSD consortium. As a clinician, Brandon is trained in the treatment of PTSD and complex disorder profiles involving substance misuse, stress, and depression using largely cognitive-behavioral, dialectical-behavioral, and acceptance-commitment modalities.


Evan Wood, MD, PhD, FASAM, FRCPC

Chief Medical Officer at Numinus

Dr. Evan Wood has published over 650 peer-reviewed scientific articles and made major contributions to the establishment of innovative policy and therapeutic programs. Early in his career, Dr. Wood’s research contributed to revision of international guidelines for the treatment and prevention of HIV infection among persons who use drugs. Subsequently, he led efforts that have contributed to the regulation of adult cannabis use in Canada, the establishment of supervised injecting facilities as a standard of care for overdose prevention in Canada, and clinical therapeutic guidelines for a range of substance use disorders. Dr. Wood developed one of North America’s largest addiction medicine eduction programs and has been a Tier 1 Canada Research Chair and Professor of Medicine. As Numinus’ Chief Medical Officer, Dr. Wood is responsible for planning clinical research, assisting with protocol development, and clinical strategy within the organization.

Dr. Rick Barnett, PsyD

Co-Founder of Psychedelic Society of Vermont

Dr. Rick is a licensed clinical psychologist, licensed addictions counselor, and holds a Master's degree in clinical psychopharmacology. He founded and is CEO of CARTER, Inc (501c3 organization to address addiction), runs a private group general mental health and addiction group practice, and is co-founder of the Psychedelic Society of Vermont. Rick has been trained by MAPS for MDMA-Assisted Psychotherapy and completed a year-long psychedelic research and treatment program through the California Institute for Integral Studies. Rick offers Ketamine-Based Psychotherapy to select patients in his private practice. He has also serves on several boards with Vermont State Government, the Vermont Psychological Association, and the American Psychological Association. In addition, Rick has been in recovery from addiction for nearly 30 years and is an active advocate for recovery from addictions.

Kevin Franciotti, MA, LAC

Therapist & Psychedelic Program Director at Ballen Medical & Wellness

Kevin Franciotti is a Master’s-level therapist and Licensed Addiction Counselor, writer, and recovery advocate based in Denver. He is a former advisory board member for Project New Day foundation’s inaugural community-engaged public health project, Psychedelics in Recovery: Outreach and Service, focusing on support for mutual aid groups with members who integrate psychedelic experiences for ongoing addiction recovery. In 2011, Kevin underwent treatment for opioid use disorder with ibogaine, a drug derived from the iboga shrub indigenous to west-central Africa. He has previously written about his experience in various publications, including New Scientist magazine and TheFix.com.

At the Psychedelic Medicine Association, we’re always looking for ways to provide you even more value – both in education on psychedelics and in networking with your fellow members. So to this end, we’re bringing you the Psychedelic Medicine Journal Club! 

As many of you may have experienced during school or residency, journal club is a gathering where all attendees read the same journal article and discuss it in depth to provide an even greater understanding of the material (all while getting to know each other even better).

For our spring 2023 journal club, facilitated by Dr. Kate Pate, we will discuss “Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis” which appeared in volume 23, issue 2 of the International Journal of Clinical and Health PsychologyThis will be an interactive format where everyone is encouraged to turn on their camera and share your thoughts on the article – as well as meet your fellow PMA members!

So please join us for our journal club discussion on Thursday, March 30th at 5 pm Pacific, 8 pm Eastern. A link to the recording will be available afterward if you cannot make it to the live event.

Hope to see you all on the 30th!

You can find the Psychedelic Medicine Association on Twitter, LinkedIn, and on Facebook.